# Committee on Science, Space, and Technology U.S. House of Representatives

Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI. Clause 2(9)(5)

Required by House Rule XI, Clause 2(g)(5)	
1. Your Name: Keith Yamamoto	
2. Are you testifying on behalf of the Federal, or a State or local government entity?	es No
3. Are you testifying on behalf of an entity that is not a government entity?	es No
4. Other than yourself, please list which entity or entities you are representing	g:
5. Please list any Federal grants, cooperative agreements, or contracts (including subgrants or subcontracts) that you or the entity you represent have receive after October 1, 2013:	_
6. Please list any foreign government payments that you or the entity you represent the received on or after October 1, 2013:	esent have
7. If your answer to the question in item 3 in this form is "yes," please describe position or representational capacity with the entity(ies) you are representi	•
8. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	es No
9. If the answer to the question in item 3 is "yes," please list any Federal grants cooperative agreements, or contracts (including subgrants or subcontracts) received by the entities listed under the question in item 4 on or after Octob that exceed 10 percent of the revenue of the entities in the year received, incourse and amount of each grant or contract to be listed:	that were ber 1, 2013,
I certify that the above information is true and correct.  Signature:	, /17

#### MCB-1157767

(Yamamoto)

7/15/12 - 6/30/15

NSF - National Science Foundation

Impact of sumoylation and Wnt/beta-catenin signaling on nuclear receptor-regulated tissue-specific transcription

### • NSF-16155826

(Yamamoto)

7/1/16 -

6/30/21

NSF - National Science

Foundation

Addressing the precision-plasticity paradox in metazoan gene regulatory networks

## • Award Number: Not Applicable

(Yamamoto)

1/1/13 - 12/31/15

William Lawrence and Blanche Hughes Foundation *Mechanisms and therapeutics for glucocorticoid-resistant leukemia* 

# • 5 DP7 OD018420-03 (Dorman, Lindstaedt, O'Brien,

**Yamamoto)** 9/1/13 - 8/31/18

NIH/OD - National Institutes of Health/ Office of the Director

Motivating INformed Decisions (MIND): Careers for the Future Biomedical Workforce

## • 5 R21 ES026068-01

(Yamamoto)

8/5/15 - 7/31/17

NIH/NIEHS - National Institutes of Health / National Institute of Environmental Health

Sciences

Transporters for Glucocorticoids: Exploring a New Paradigm for

#### False Statements Act Certification

You are specifically advised that providing false information to this Committee/Subcommittee, or concealing material information from this Committee/Subcommittee, is a crime, and you can be punished for that. If you acknowledge this, please sign the bottom of this form and return to the Committee. This form will be made part of the hearing record.

Witness signature

Date